Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2030

" The psoriasis drugs pipeline market is based on the type of treatment (biological agents, systemic small molecule drugs and tropical therapy), mechanism of action (TNF α inhibitors, PDE4 inhibitors, interleukin inhibitors and other mechanisms of action), route of administration (oral, Parenteral and thematic) and geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report provides the value (in millions of U.S. dollars) for the aforementioned market segments.

The market value of psoriasis drugs in 2021 is estimated to be USD ~15 billion and is expected to expand at a compound annual growth rate of ~10% during the forecast period of 2022-2030. 

 

In March 2020, the International Psoriasis Council (IPC) recommended that doctors suspend or postpone the prescription of immunosuppressive drugs. However, in late September 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania and 16 other research institutions in the United States and Canada worked with the National Psoriasis Foundation to develop a plan to take care of psoriasis during the coronavirus Patients guide.

The scientists found that there is no evidence that medical interventions for psoriasis and psoriatic arthritis need to be interrupted or modified to minimize the risk of COVID-19. The guide is expected to resume market growth. The increasing disease burden and demand for psoriasis drugs in emerging economies, as well as the increase in psoriasis research and drugs under development, are the main factors leading to market growth. 

New oral medications opened the way for patients who hate needles. For example, Bristol-Myers Squibb currently has oral TYK2 inhibitor BMS-986165, which has been found to be similar in efficacy to TNF-α inhibitors. This should be the determining factor for better acceptance by patients who do not receive injections. In addition, in February 2019, the biotechnology company Janssen Biotech Inc. received TREMFYA approved by the U.S. Food and Drug Administration for the treatment of severe plaque psoriasis. 

 

In addition, major players in the market participate in various business strategies , Such as product launches to expand its product portfolio and gain a competitive advantage in the market. For example, in October 2018, Sun Pharmaceuticals Industries Ltd announced the launch of a new drug "Item" for the treatment of plaque psoriasis. Due to the above factors, the market is expected to experience high growth rates during the forecast period. However, the adverse side effects and high treatment costs of most existing drugs are factors that are expected to hinder market growth.

 

REPORT SCOPE : 

Psoriasis is a genetic disease that may or may not exist at birth, but it may also be caused by certain environmental and genetic factors. People’s changing lifestyles and their increasing tendency to drink and smoke, unhealthy diets and sedentary life make people more susceptible to this disease. 

The psoriasis drug market is based on treatment type (biological drugs, systemic small molecule drugs and tropical therapy), mechanism of action (TNFα inhibitors, PDE4 inhibitors, interleukin inhibitors and other mechanisms of action), and route of administration (oral, intestinal) External and local) and geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report provides the value of the previous market segment (millions of dollars), and the value of the market segment (millions of dollars) by treatment type, mechanism of action, and route of administration, but no sub-segments in the segment The action mechanism of each country foreseen within the scope.

 

MAIN MARKET TRENDS: 

Interleukin inhibitors are expected to record high compound annual growth rates during the forecast period. Interleukin inhibitors are expected to show the fastest growth during the forecast period. The factor that contributes to interleukin inhibitors is their increased safety and effectiveness compared with other types of psoriasis drugs, which has been leading to more adoption by patients. For example, Taltz sales in 2019 increased by 46% from $937.5 million in 2018 to $1.3664 billion. 

The main approved antibodies targeting interlunkins include Taltz (Ixekizumab), Cosentyx (Secukinumab), Siliq (Brodalumab), Tremfya (Guseylumumab), Tildrakizumab) and SKYRIZI (Risankizumab). In March 2019, AbbVie Inc., a major market player, received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of interleukin 23 (IL-23) inhibitor SKYRIZI (Risankizumab). Plaque psoriasis, systemic pustular psoriasis and erythroderma-type psoriasis, etc. 

 

The company also received SKYRIZI approval in 2018 as a new treatment for plaque psoriasis in Europe. All these approvals in the market have further promoted the growth of this segment. However, since psoriasis is not an emergency, the ongoing COVID-19 pandemic has affected the market, as most of the interleukin I + D have ceased to focus on the development of COVID.

North America dominates the market and is expected to do so during the forecast period 2022-2030. North America has been one of the regions hardest hit by the ongoing COVID-19 pandemic. The growth of the psoriasis market is expected to slow to some extent, as patients avoid visiting dermatology clinics for psoriasis treatment. In addition to restrictions on non-emergency medical services, the regional government’s new regulations have forced several participants in the dermatology drug market to suspend commercial operations, which has also affected the growth of the market. 

The market during the forecast period. In North America, the United States has the largest market share due to the high prevalence of psoriasis. According to the article "Prevalence of Psoriasis in Children and Adolescents in the United States: A Claim-Based Analysis " published in February 2018, the prevalence of psoriasis is estimated to be 128 cases per 100,000 people. 

Other factors that promote the development of the market include favorable government initiatives and advanced medical infrastructure. Due to the increasing prevalence of certain diseases, and due to widespread acceptance in North American countries, the European-based company MC2 Therapeutics signed a cooperation agreement with EPI Health LLC in August 2020 to sell its WYNSORS cream (Carbosan Ene and betamethasone) dipropionate, p / p 0.005% / 0.064%) in the US market. WYNSORS cream was approved by the U.S. Food and Drug Administration (FDA) in July 2020 for the topical indication of plaque psoriasis in adults. WYNZORA Cream, which will be launched in the US market soon, may further promote market growth in this region.

 

COMPETITIVE LANDSCAPE : 

The psoriasis drug market is moderately competitive and consists of several major players. In terms of market share, few major players currently dominate the market. The company develops new products by adopting strategies including alliances and acquisitions, thereby focusing on business expansion in developing regions or emerging markets such as India, China, and South Korea. For example, in August 2019, Amgen acquired Otezla, a biopharmaceutical company dedicated to the production of psoriasis drugs, for $13.4 billion. In July 2019, Cipla cooperated with biopharmaceutical company Alvotech to commercialize AVT02. AVT02 is a biosimilar of Adalimumab, used to treat plaque psoriasis and rheumatoid arthritis.

 

UPDATE : 

In November 2020, Bristol-Myers Squibb received a positive result of POETYK PSO-1, which is the first pivotal phase 3 trial to evaluate deucvacitinib (BMS-986165), a new oral selective tyrosine kinase 2 (TYK2) inhibitors are used for treatment. In May 2020, Lupin Limited and Mylan launched the biosimilar etanercept Nepexto in Germany, which was approved by the European Commission in May 2020 for the treatment of psoriatic arthritis and plaque Psoriasis and other indications. In July 2020, Fujifilm Concord Kylin Biologics was approved by the Japanese regulatory authority to produce and sell the first adalimumab biosimilar in the island country for the treatment of psoriasis vulgaris, arthritic psoriasis, and psoriasis. Blister psoriasis, ankylosing spondylitis, intestinal Behcet's disease and Crohn's disease polyarticular juvenile idiopathic arthritis."
 

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.